VYVGART® (efgartigimod)
Generalized Myasthenia Gravis
Key Facts
About Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileAbout Zai Lab
Founded in 2014 by Dr. Samantha Du, Zai Lab has grown into a leading global biopharma with a dual headquarters in China and the U.S. The company combines in-licensed assets with strategic partnerships and internal R&D to build a robust pipeline, with eight products already on the market in China. Its mission is to bridge gaps in global health by advancing breakthrough therapies for patients with significant unmet medical needs.
View full company profileTherapeutic Areas
Other Generalized Myasthenia Gravis Drugs
| Drug | Company | Phase |
|---|---|---|
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |